CBD and Anxiety: Promising Signal, Weak Evidence Base

A 2024 narrative review cataloguing completed and ongoing clinical trials of cannabidiol for anxiety disorders finds that the vast majority are underpowered, exploratory, and heterogeneous in design, concluding that the field remains far from generating the confirmatory evidence needed to support clinical recommendations.

Why This Matters

Anxiety disorders are among the most prevalent psychiatric conditions worldwide, affecting hundreds of millions of people, and existing pharmacotherapies carry significant limitations including delayed onset, incomplete response, and tolerability concerns. Cannabidiol has attracted substantial public and scientific interest as a potential anxiolytic with a favorable side effect profile, and patients increasingly ask clinicians about it. This review arrives at a moment when commercial availability of CBD products far outpaces the clinical evidence supporting their use, making an honest accounting of the trial landscape especially urgent for practitioners navigating patient expectations.

Clinical Summary

Anxiety disorders, including generalized anxiety disorder, social anxiety disorder, panic disorder, and post-traumatic stress disorder, remain inadequately managed in a substantial proportion of patients despite available treatments. Published in the Journal of Cannabis Research in 2024, this narrative review by Skelley and colleagues surveys the current landscape of CBD clinical trials targeting anxiety, drawing on preclinical evidence suggesting that CBD modulates serotonergic signaling via the 5-HT1A receptor and interacts with the endocannabinoid system in ways that could reduce anxiety-related neural activity. The review does not employ systematic search methodology or meta-analytic pooling; instead, it narratively catalogues trial characteristics to assess the field’s readiness for clinical translation.

The authors identified only six completed and 22 ongoing or planned clinical trials of CBD for anxiety disorders. Most trials are single-center and exploratory, with widely varying CBD doses, formulations, treatment durations, and sample sizes. Only two trials are multicenter in design. The review does not pool efficacy outcomes, so no quantitative estimate of CBD’s treatment effect is provided. The authors conclude that sufficiently powered, multicenter, randomized controlled trials targeting specific anxiety disorder subtypes with standardized dosing and robust primary endpoints are needed before CBD can be recommended for clinical management. Notably, two of the review’s authors are affiliated with Vectura Fertin Pharma, a company with commercial interest in CBD products, a conflict of interest that warrants consideration when evaluating the review’s framing.

Dr. Caplan’s Take

This review does something genuinely useful: it lays out, in unflinching detail, how thin the clinical trial base for CBD in anxiety actually is. Patients come to my clinic regularly asking about CBD for anxiety, often already using it, and they deserve an honest answer. The preclinical signal is real and the mechanistic rationale is plausible, but six completed trials and a collection of small, heterogeneous ongoing studies do not constitute an evidence base that supports prescriptive confidence. The industry affiliation of two authors does not invalidate the review, but it does mean the optimistic framing of CBD’s “promise” deserves independent scrutiny.

In practice, I do not discourage patients from discussing CBD use, but I am transparent that we lack the data to recommend specific doses, formulations, or treatment durations for any defined anxiety disorder. When a patient is already using CBD and reports benefit, I focus on ensuring they are not substituting it for treatments with stronger evidence, monitoring for drug interactions, and documenting their experience. I continue to prioritize evidence-based pharmacotherapy and psychotherapy as first-line approaches while watching this space carefully for the confirmatory trials this review correctly identifies as missing.

Clinical Perspective

This review sits squarely in the early-to-middle phase of the research arc for CBD in anxiety. It confirms what many clinicians already suspect: the preclinical foundation is scientifically interesting, but the clinical trial infrastructure has not yet matured to the point where it can answer the questions that matter most. The evidence does not support recommending CBD as a treatment for any specific anxiety disorder. It does, however, support continued investigation. Clinicians should be cautious about framing CBD as “emerging” therapy in ways that patients may interpret as tacit endorsement, particularly given the commercial pressures driving public enthusiasm ahead of the science.

From a pharmacological standpoint, CBD inhibits CYP3A4 and CYP2C19, creating meaningful interaction potential with commonly prescribed anxiolytics and antidepressants including sertraline, citalopram, and benzodiazepines. Hepatotoxicity signals have emerged at higher doses in epilepsy trials, and the lack of standardized formulations in consumer products introduces additional uncertainty about what patients are actually ingesting. Clinicians seeing patients who use CBD should routinely screen for concurrent medications, document CBD product details where possible, and monitor liver function when use is sustained or doses are high. This is the single most actionable step available now: systematic documentation of CBD use in psychiatric patients to build the observational foundation the field still lacks.

Study at a Glance

Study Type

Narrative review

Population

Adults with anxiety disorders (SAD, GAD, PTSD, panic disorder); preclinical models also discussed

Intervention

Cannabidiol (CBD), various doses and formulations across reviewed trials

Comparator

Varies by trial; placebo in most completed RCTs

Primary Outcomes

Anxiety symptom measures (varied across trials; no pooled outcome)

Sample Size

6 completed trials and 22 ongoing/planned trials reviewed

Journal

Journal of Cannabis Research

Year

2024

DOI or PMID

Not provided in source data

Funding Source

Two authors affiliated with Vectura Fertin Pharma Switzerland SA

What Kind of Evidence Is This

This is a narrative review that surveys completed and ongoing clinical trials of CBD for anxiety disorders without employing systematic search methodology, PRISMA reporting, or meta-analytic pooling. Narrative reviews occupy a lower tier of the evidence hierarchy than systematic reviews because their conclusions depend on the completeness and representativeness of the literature the authors chose to include. The single most important inference constraint is that the absence of a transparent, reproducible search protocol means relevant trials may have been missed or included selectively, and the review’s landscape assessment cannot be independently verified for completeness.

How This Fits With the Broader Literature

The findings here are broadly consistent with prior assessments of the cannabinoid therapeutics field. A 2019 systematic review by Black and colleagues in The Lancet Psychiatry similarly concluded that evidence for cannabinoids in mental health conditions, including anxiety, was limited and of low quality. The present review extends that earlier work by cataloguing trials initiated since 2019, and it reaches essentially the same conclusion: the field has grown in volume but not yet in rigor. Small, positive signals from acute-dosing studies in social anxiety disorder, notably the work by Crippa and colleagues, continue to be cited as foundational, but no large confirmatory trial has yet replicated or extended those findings in a clinically definitive way. The persistence of this evidence gap despite years of public and commercial enthusiasm underscores the disconnect between consumer adoption and scientific substantiation.

Common Misreadings

The most likely overinterpretation is treating this review as evidence that CBD “works” for anxiety because it describes ongoing trials and cites positive preclinical data. The review explicitly does the opposite: it documents that the evidence base is insufficient. Cataloguing 28 trials is not the same as demonstrating efficacy across those trials. Readers should also resist interpreting the large number of ongoing studies as evidence that confirmation is imminent. Most of these trials are small, single-center, and exploratory in design, meaning they are individually unlikely to resolve the clinical uncertainty the review identifies. The industry affiliation of two authors further warrants caution against accepting the review’s more optimistic framings at face value.

Bottom Line

This narrative review provides a useful map of where CBD anxiety research currently stands and confirms that the territory remains largely unexplored by rigorous standards. The six completed trials are small and heterogeneous, the 22 ongoing trials are mostly exploratory, and no study yet provides the confirmatory, disorder-specific evidence needed to guide clinical practice. CBD remains a plausible but unproven anxiolytic. Clinicians should document patient use, monitor for interactions, and await adequately powered trials before recommending it.

References

1. Skelley JW, Hubbard CD, Kadiam S, Norris LM. Cannabidiol (CBD) for anxiety: a review of completed and ongoing clinical trials. Journal of Cannabis Research. 2024. (Full DOI not provided in source data.)
2. Black N, Stockings E, Campbell G, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. The Lancet Psychiatry. 2019;6(12):995-1010. doi:10.1016/S2215-0366(19)30401-8
3. Crippa JA, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. Journal of Psychopharmacology. 2011;25(1):121-130. doi:10.1177/0269881110379283